|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IER3 |
Gene summary for IER3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IER3 | Gene ID | 8870 |
| Gene name | immediate early response 3 | |
| Gene Alias | DIF-2 | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A1U9X7X2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8870 | IER3 | GSM4909281 | Human | Breast | IDC | 2.69e-24 | -7.91e-01 | 0.21 |
| 8870 | IER3 | GSM4909285 | Human | Breast | IDC | 2.45e-10 | -3.83e-01 | 0.21 |
| 8870 | IER3 | GSM4909286 | Human | Breast | IDC | 2.16e-53 | -1.09e+00 | 0.1081 |
| 8870 | IER3 | GSM4909287 | Human | Breast | IDC | 2.09e-06 | -5.07e-01 | 0.2057 |
| 8870 | IER3 | GSM4909290 | Human | Breast | IDC | 3.28e-08 | -5.47e-01 | 0.2096 |
| 8870 | IER3 | GSM4909291 | Human | Breast | IDC | 1.70e-06 | -6.04e-01 | 0.1753 |
| 8870 | IER3 | GSM4909294 | Human | Breast | IDC | 1.01e-23 | -7.67e-01 | 0.2022 |
| 8870 | IER3 | GSM4909296 | Human | Breast | IDC | 4.80e-19 | -6.09e-01 | 0.1524 |
| 8870 | IER3 | GSM4909297 | Human | Breast | IDC | 4.59e-09 | -2.42e-01 | 0.1517 |
| 8870 | IER3 | GSM4909298 | Human | Breast | IDC | 2.17e-11 | -5.38e-01 | 0.1551 |
| 8870 | IER3 | GSM4909302 | Human | Breast | IDC | 4.50e-30 | -9.36e-01 | 0.1545 |
| 8870 | IER3 | GSM4909304 | Human | Breast | IDC | 1.08e-08 | -5.41e-01 | 0.1636 |
| 8870 | IER3 | GSM4909306 | Human | Breast | IDC | 4.24e-04 | 2.93e-01 | 0.1564 |
| 8870 | IER3 | GSM4909308 | Human | Breast | IDC | 4.14e-03 | 2.70e-01 | 0.158 |
| 8870 | IER3 | GSM4909311 | Human | Breast | IDC | 1.46e-21 | -3.13e-01 | 0.1534 |
| 8870 | IER3 | GSM4909312 | Human | Breast | IDC | 4.68e-02 | -1.80e-01 | 0.1552 |
| 8870 | IER3 | GSM4909315 | Human | Breast | IDC | 1.02e-26 | -7.96e-01 | 0.21 |
| 8870 | IER3 | GSM4909316 | Human | Breast | IDC | 1.93e-13 | -1.02e+00 | 0.21 |
| 8870 | IER3 | GSM4909319 | Human | Breast | IDC | 7.51e-39 | 2.80e-01 | 0.1563 |
| 8870 | IER3 | GSM4909320 | Human | Breast | IDC | 1.67e-05 | -6.83e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051222110 | Oral cavity | LP | positive regulation of protein transport | 123/4623 | 303/18723 | 6.05e-10 | 2.96e-08 | 123 |
| GO:200102018 | Oral cavity | LP | regulation of response to DNA damage stimulus | 82/4623 | 219/18723 | 1.71e-05 | 2.97e-04 | 82 |
| GO:00443461 | Oral cavity | LP | fibroblast apoptotic process | 13/4623 | 22/18723 | 6.11e-04 | 5.58e-03 | 13 |
| GO:20002691 | Oral cavity | LP | regulation of fibroblast apoptotic process | 10/4623 | 19/18723 | 8.09e-03 | 4.40e-02 | 10 |
| GO:200102024 | Oral cavity | EOLP | regulation of response to DNA damage stimulus | 47/2218 | 219/18723 | 3.47e-05 | 4.85e-04 | 47 |
| GO:200102015 | Prostate | BPH | regulation of response to DNA damage stimulus | 60/3107 | 219/18723 | 3.58e-05 | 3.92e-04 | 60 |
| GO:200102016 | Prostate | Tumor | regulation of response to DNA damage stimulus | 59/3246 | 219/18723 | 2.37e-04 | 2.01e-03 | 59 |
| GO:200102020 | Skin | AK | regulation of response to DNA damage stimulus | 40/1910 | 219/18723 | 1.93e-04 | 2.19e-03 | 40 |
| GO:2001020111 | Skin | cSCC | regulation of response to DNA damage stimulus | 87/4864 | 219/18723 | 5.38e-06 | 7.75e-05 | 87 |
| GO:200102025 | Thyroid | HT | regulation of response to DNA damage stimulus | 27/1272 | 219/18723 | 1.95e-03 | 1.73e-02 | 27 |
| GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
| GO:1904951113 | Thyroid | PTC | positive regulation of establishment of protein localization | 175/5968 | 319/18723 | 1.10e-17 | 1.12e-15 | 175 |
| GO:0051222113 | Thyroid | PTC | positive regulation of protein transport | 163/5968 | 303/18723 | 1.58e-15 | 1.16e-13 | 163 |
| GO:000688817 | Thyroid | PTC | endoplasmic reticulum to Golgi vesicle-mediated transport | 83/5968 | 130/18723 | 6.19e-14 | 3.52e-12 | 83 |
| GO:2001020112 | Thyroid | PTC | regulation of response to DNA damage stimulus | 113/5968 | 219/18723 | 9.37e-10 | 2.77e-08 | 113 |
| GO:00301986 | Thyroid | PTC | extracellular matrix organization | 124/5968 | 301/18723 | 3.75e-04 | 2.53e-03 | 124 |
| GO:00430626 | Thyroid | PTC | extracellular structure organization | 124/5968 | 302/18723 | 4.38e-04 | 2.92e-03 | 124 |
| GO:00452296 | Thyroid | PTC | external encapsulating structure organization | 124/5968 | 304/18723 | 5.96e-04 | 3.79e-03 | 124 |
| GO:19030554 | Thyroid | PTC | positive regulation of extracellular matrix organization | 16/5968 | 25/18723 | 9.53e-04 | 5.72e-03 | 16 |
| GO:19030533 | Thyroid | PTC | regulation of extracellular matrix organization | 26/5968 | 48/18723 | 1.13e-03 | 6.59e-03 | 26 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IER3 | SNV | Missense_Mutation | c.371C>T | p.Pro124Leu | p.P124L | P46695 | protein_coding | deleterious(0.05) | benign(0.056) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| IER3 | SNV | Missense_Mutation | c.7C>T | p.His3Tyr | p.H3Y | P46695 | protein_coding | tolerated(0.36) | benign(0.442) | TCGA-DD-A73D-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| IER3 | SNV | Missense_Mutation | c.194N>C | p.Val65Ala | p.V65A | P46695 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |